WeightWatchers shifts to value-based care with GLP-1 strategy
WeightWatchers (WW) recently completed a broader financial reorganization, realigning leadership with a sharper focus on clinical innovation and women’s health, including menopause support. The reorganization includes appointing a chief medical officer to lead a more integrated, medically informed approach.
WW’s reorganization bankruptcy was driven by mounting debt and pressure from newer weight-loss therapy products, namely GLP-1 drugs like Ozempic and Wegovy. It was also impacted by a shifting landscape where traditional …






![Why physicians must lead the vetting of medical AI [PODCAST]](https://kevinmd.com/wp-content/uploads/The-Podcast-by-KevinMD-WideScreen-3000-px-3-190x100.jpg)


![Rebuilding the backbone of health care [PODCAST]](https://kevinmd.com/wp-content/uploads/Design-3-190x100.jpg)

![A financial vision to define your retirement [PODCAST]](https://kevinmd.com/wp-content/uploads/Design-4-190x100.jpg)
